… III trials were identified based on the statement of the authors in the published reports and
were verified by contacting the group chair. A small minority of the phase III trials … phase III trials …

… Forty-three randomized, controlled phase III trials initiated between 1973 and 1994 in North
… with advanced non–small-cell lung cancer were identified. Ten trials were found to be …

… chemo-naïve patients with advanced non-small cell lung cancer (NSCLC) enrolled in phase
III trials. The analysis similarly revealed a very small increase in patient survival (3.61 days …

… status patients with stage III non–small cell lung cancer. However, it is not known whether
sequential or concurrent delivery of these therapies is the optimal combination strategy. …

… Results from three phase III trials exploring the efficacy of this … 1 Outcomes of immunotherapy
trials in small-cell lung cancer … In this open-label, randomized, phase III trial, 268 patients …

… Phase II trial of biweekly irinotecan plus gemcitabine … II study of imatinib in patients with
small cell lung cancer Clin … II study of imatinib in patients with small cell lung cancer. Clin …

… From September 1991 through December 1996, 62 patients with completely resected small
cell lung cancer who were less than 76 years of age from 17 centers were entered in the trial…

… Docetaxel (75 mg/m 2 ) was approved for second-line treatment of advanced non-small-cell
lung cancer after findings from two phase III trials TAX 317 and TAX 320 showed improved …

… Adjuvant cisplatin-based chemotherapy (ACT) is now an accepted standard for completely
resected stage II and III A non–small-cell lung cancer (NSCLC). Long-term follow-up is …

… Initially, a small phase III trial performed in Japan reported … However, 2 subsequent large
phase III trials performed in the … A randomized phase II trial (n=70) comparing carboplatin and …